Global Irritable Bowel Syndrome (IBS) Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Irritable Bowel Syndrome (IBS) Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Irritable bowel syndrome (IBS) is defined as recurrent abdominal pain or discomfort that occurs in association with altered bowel habits over a period of at least 3 months. The disorder is classified into three main subtypes, according to the predominant bowel habits presentedconstipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D), and mixed-presentation IBS (IBS-M). IBS is among the most common gastrointestinal disorders, with an estimated pooled international IBS prevalence rate of about 11.2%.
Irritable Bowel Syndrome (IBS) report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Irritable Bowel Syndrome (IBS) market is projected to reach US$ 12740 million in 2034, increasing from US$ 4737.2 million in 2022, with the CAGR of 15.0% during the period of 2024 to 2034. Demand from Women and Men are the major drivers for the industry.
North America is the largest region of Irritable Bowel Syndrome (IBS), with a market share about 75%. Allergan, Valeant Pharmaceuticals, Takeda, Sucampo Pharmaceuticals and McNeil Consumer Healthcare are the top 5 manufacturers of industry, and they had about 80% combined market share.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Irritable Bowel Syndrome (IBS) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
Bausch Health
Allergan
Takeda
Sucampo Pharmaceuticals (Mallinckrodt)
Sebela Pharmaceuticals Inc
Astellas Pharmaceuticals
Segment by Type
IBS-D Drug
IBS-C Drug
Others
Women
Men
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Irritable Bowel Syndrome (IBS) market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Irritable Bowel Syndrome (IBS) introduction, etc. Irritable Bowel Syndrome (IBS) Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12QYResearch’s Conclusions of Irritable Bowel Syndrome (IBS) market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by QYResearch.
Irritable Bowel Syndrome (IBS) report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Irritable Bowel Syndrome (IBS) market is projected to reach US$ 12740 million in 2034, increasing from US$ 4737.2 million in 2022, with the CAGR of 15.0% during the period of 2024 to 2034. Demand from Women and Men are the major drivers for the industry.
North America is the largest region of Irritable Bowel Syndrome (IBS), with a market share about 75%. Allergan, Valeant Pharmaceuticals, Takeda, Sucampo Pharmaceuticals and McNeil Consumer Healthcare are the top 5 manufacturers of industry, and they had about 80% combined market share.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Irritable Bowel Syndrome (IBS) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
Bausch Health
Allergan
Takeda
Sucampo Pharmaceuticals (Mallinckrodt)
Sebela Pharmaceuticals Inc
Astellas Pharmaceuticals
Segment by Type
IBS-D Drug
IBS-C Drug
Others
Segment by Application
Women
Men
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Irritable Bowel Syndrome (IBS) market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Irritable Bowel Syndrome (IBS) introduction, etc. Irritable Bowel Syndrome (IBS) Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12QYResearch’s Conclusions of Irritable Bowel Syndrome (IBS) market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices